Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: C. albicans Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 11, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00006113
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide, Candida albicans skin test reagent
Biological · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Randomized Double-Blind Controlled Clinical Trial

NCT04320628
View directory record Official record
Conditions
Chronic Wounds, Acute Wounds
Interventions
AnaSept®, NSS
Device · Other
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

Fluconazole Prophylaxis of Thrush in AIDS

NCT00001542
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Candidiasis, Oral Candidiasis
Interventions
fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

NCT00496197
View directory record Official record
Conditions
Candidiasis
Interventions
Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 11, 2026, 5:23 PM EDT
Withdrawn Not applicable Interventional

Cleanser for Acute Wounds

NCT05422144
View directory record Official record
Conditions
Acute Wound
Interventions
Antimicrobial Skin & Wound Cleanser (AWC), Antimicrobial Wound Gel (AWG)
Device
Lead sponsor
Rochal Industries LLC
Industry
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunologic Profile of Chronically Photodamaged Skin

NCT02889159
View directory record Official record
Conditions
Photoaged Skin, Normal Skin
Interventions
Candida albicans antigen, histamine phosphate, imiquimod 5% cream, Tape Stripping
Biological · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

NCT02393417
View directory record Official record
Conditions
Warts
Interventions
CANDIN, Placebo
Biological · Other
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Encinitas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 11, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

NCT02996448
View directory record Official record
Conditions
Autosomal-dominant Hyper-IgE Syndrome
Interventions
NDV-3A
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 11, 2026, 5:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
View directory record Official record
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent
Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 11, 2026, 5:23 PM EDT
Completed No phase listed Observational

Retrospective Chart Review of Candida Fungemia

NCT03827330
View directory record Official record
Conditions
Candida Fungemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Candin Safety & Efficacy Study for the Treatment of Warts

NCT01757392
View directory record Official record
Conditions
Warts, Human Papilloma Virus
Interventions
Candida albicans Skin Test Antigen
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Fort Smith, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

Study With Candida Antigen for Treatment of Warts

NCT00569231
View directory record Official record
Conditions
Warts, HPV
Interventions
Candida Antigen
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

Candin for the Treatment of Common Warts

NCT05889845
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris)
Interventions
Candin, Intradermal Solution, Placebo
Drug
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

NCT04896086
View directory record Official record
Conditions
Influenza, Seasonal Influenza
Interventions
VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 11, 2026, 5:23 PM EDT
Completed No phase listed Observational

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

NCT00721487
View directory record Official record
Conditions
Fungal Infection by Site
Interventions
Fluconazole
Drug
Lead sponsor
CPL Associates
Other
Eligibility
4 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

NCT03930745
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Placebo, TOL-463
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • La Jolla, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 11, 2026, 5:23 PM EDT